Tagged with API

Czech Republic In 1996 Jiří Žák, chairman & current CEO of FARMAK, borrowed half a billion Czech crowns to take over a state-owned producer of vitamins for which he had started working almost 30 years previously.   My goal is to continue reinvesting our profits to keep growing and leave behind a…

Czech Republic Ladislav Drož, CEO of APIGENEX, reveals the company’s strategy to survive after a leadership change and a reshuffling of the small-molecule science operations at their main client, Novo Nordisk. Drož also discusses APIGENEX’s future goals of investing in robotics and automation. APIGENEX’s services include chemistry, experimental pharmacology, clinical pharmacology, registration…

Czech Republic In 1996, Jiří Žák, chairman & current CEO of FARMAK, took over the state-owned producer of vitamins FARMAKON where he previously worked for 30 years and turned it into a flourishing private company focused on the research, development, and production of active pharmaceutical ingredients (APIs), intermediates, and specialized chemicals. Žák shares the early success…

Taiwan Lily Wu, CEO of PapiVax, discusses the biotechs initiative pipeline for the treatment of HPV related diseases and cancers and goes on to elaborate the company’s development and future partnership strategies. Wu also discusses the unique structure of PapiVax as a lean, R&D and research-driven biotech which is powered by…

Opinion Greg Reh comments on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which…

Korea Kukjeon, originally a leading Korean pharmaceutical wholesaler, has in recent years expanded into API manufacturing. Its president, Jay Hong, explains his high-risk strategy to pursue new API business opportunities, and his plan to penetrate global markets from Japan to Europe.   My preferred strategy is to go down the path…

Korea Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his experience in the public sector now helps him lead a private sector company. He also offers his insights into Daewoong Bio’s diversified business model and highlights the need for internationalization.…

Spain Joël Jean-Mairet, general partner of Ysios Capital, discusses the major trends impacting the venture capital ecosystem in the life sciences sector and the complexity of attracting new investors to the market. Furthermore, he highlights the firm’s success stories and the key steps required for Spain to be a biotech hub…

UK Heading FUJIFILM Diosynth Biotechnologies’ operations globally, Steve Bagshaw speaks out about the excellence of science in the UK and how it fits the company’s plans to build up a solid presence in the development and manufacturing of new advanced treatments. He further explains how the company has been able to…

UK Chief Executive since 2011, Peter Coleman introduces Cobra Biologics and highlights challenges both domestically and globally in the biotech space for CDMOs; he addresses funding opportunities within the public and private sector and Cobra Biologics’ ambitious plans for 2022. Can you please introduce Cobra Biologics to our international readers? “The…

Malta Antonio Sommei, plant director of Amino Chemicals, the leading API manufacturer on the island of Malta, documents the impact of the recent merger with ABA Chemical Corporation on local operations, the increased capacities the company will have, and their focus on expansion to new markets globally with the intention of…

India Dr. Satyanarayana Chava, founder and CEO of Laurus Labs, provides insights into the distinctive model that has allowed Laurus to become one of the world’s leading API companies as well as the partner of choice of the most prominent MNCs globally – after only 13 years of existence. He also…